SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:DiVA.org:uu-395562"
 

Sökning: onr:"swepub:oai:DiVA.org:uu-395562" > Downregulation of E...

  • Lopez-Luque, JuditBellvitge Biomed Res Inst IDIBELL, Oncobell Program, TGP B, Barcelona, Spain;Bellvitge Biomed Res Inst IDIBELL, Oncobell Program, Canc Grp, Barcelona, Spain;Inst Salud Carlos III, Oncol Program, CIBEREHD, Natl Biomed Res Inst Liver & Gastrointestinal Dis, Madrid, Spain (författare)

Downregulation of Epidermal Growth Factor Receptor in hepatocellular carcinoma facilitates Transforming Growth Factor-beta-induced epithelial to amoeboid transition

  • Artikel/kapitelEngelska2019

Förlag, utgivningsår, omfång ...

  • ELSEVIER IRELAND LTD,2019
  • electronicrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:uu-395562
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-395562URI
  • https://doi.org/10.1016/j.canlet.2019.08.011DOI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • The Epidermal Growth Factor Receptor (EGFR) and the Transforming Growth Factor-beta (TGF-beta) are key regulators of hepatocarcinogenesis. Targeting EGFR was proposed as a promising therapy; however, poor success was obtained in human hepatocellular carcinoma (HCC) clinical trials. Here, we describe how EGFR is frequently downregulated in HCC patients while TGF-beta is upregulated. Using 2D/3D cellular models, we show that after EGFR loss, TGF-beta is more efficient in its pro-migratory and invasive effects, inducing epithelial to amoeboid transition. EGFR knock-down promotes loss of cell-cell and cell-to-matrix adhesion, favouring TGF-beta-induced actomyosin contractility and acquisition of an amoeboid migratory phenotype. Moreover, TGF-beta upregulates RHOC and CDC42 after EGFR silencing, promoting Myosin II in amoeboid cells. Importantly, low EGFR combined with high TGFBI or RHOC/CDC42 levels confer poor patient prognosis. In conclusion, this work reveals a new tumour suppressor function for EGFR counteracting TGF-beta-mediated epithelial to amoeboid transitions in HCC, supporting a rational for targeting the TGF-beta pathway in patients with low EGFR expression. Our work also highlights the relevance of epithelial to amoeboid transition in human tumours and the need to better target this process in the clinic.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Bertran, EstherBellvitge Biomed Res Inst IDIBELL, Oncobell Program, TGP B, Barcelona, Spain;Bellvitge Biomed Res Inst IDIBELL, Oncobell Program, Canc Grp, Barcelona, Spain;Inst Salud Carlos III, Oncol Program, CIBEREHD, Natl Biomed Res Inst Liver & Gastrointestinal Dis, Madrid, Spain (författare)
  • Crosas-Molist, EvaQueen Mary Univ London, Barts Canc Inst, Canc Res UK Ctr Excellence, John Vane Sci Bldg Charterhouse Sq, London EC1M 6BQ, England (författare)
  • Maiques, OscarQueen Mary Univ London, Barts Canc Inst, Canc Res UK Ctr Excellence, John Vane Sci Bldg Charterhouse Sq, London EC1M 6BQ, England (författare)
  • Malfettone, AndreaBellvitge Biomed Res Inst IDIBELL, Oncobell Program, TGP B, Barcelona, Spain;Bellvitge Biomed Res Inst IDIBELL, Oncobell Program, Canc Grp, Barcelona, Spain (författare)
  • Caja, LaiaUppsala universitet,Science for Life Laboratory, SciLifeLab(Swepub:uu)laica659 (författare)
  • Serrano, TeresaInst Salud Carlos III, Oncol Program, CIBEREHD, Natl Biomed Res Inst Liver & Gastrointestinal Dis, Madrid, Spain;Univ Hosp Bellvitge, Pathol Anat Serv, Barcelona, Spain (författare)
  • Ramos, EmilioInst Salud Carlos III, Oncol Program, CIBEREHD, Natl Biomed Res Inst Liver & Gastrointestinal Dis, Madrid, Spain;Univ Hosp Bellvitge, Liver Transplant Unit, Dept Surg, Barcelona, Spain (författare)
  • Sanz-Moreno, VictoriaQueen Mary Univ London, Barts Canc Inst, Canc Res UK Ctr Excellence, John Vane Sci Bldg Charterhouse Sq, London EC1M 6BQ, England (författare)
  • Fabregat, IsabelBellvitge Biomed Res Inst IDIBELL, Oncobell Program, TGP B, Barcelona, Spain;Bellvitge Biomed Res Inst IDIBELL, Oncobell Program, Canc Grp, Barcelona, Spain;Inst Salud Carlos III, Oncol Program, CIBEREHD, Natl Biomed Res Inst Liver & Gastrointestinal Dis, Madrid, Spain;Univ Barcelona, Fac Med & Hlth Sci, Dept Physiol Sci, Barcelona, Spain (författare)
  • Bellvitge Biomed Res Inst IDIBELL, Oncobell Program, TGP B, Barcelona, Spain;Bellvitge Biomed Res Inst IDIBELL, Oncobell Program, Canc Grp, Barcelona, Spain;Inst Salud Carlos III, Oncol Program, CIBEREHD, Natl Biomed Res Inst Liver & Gastrointestinal Dis, Madrid, SpainQueen Mary Univ London, Barts Canc Inst, Canc Res UK Ctr Excellence, John Vane Sci Bldg Charterhouse Sq, London EC1M 6BQ, England (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Cancer Letters: ELSEVIER IRELAND LTD464:Nov, s. 15-240304-38351872-7980

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy